Zealand Pharma
Clinical trials sponsored by Zealand Pharma, explained in plain language.
A biopharmaceutical company focused on peptide-based medicines for metabolic and gastrointestinal diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could a weekly shot free short bowel patients from IV bags?
Disease control Recruiting nowThis phase 3 trial tests glepaglutide, a synthetic hormone given as a twice-weekly injection, in 90 adults with short bowel syndrome who rely on IV nutrition. The goal is to see if the drug can safely reduce the amount of IV support needed. Participants will be randomly assigned …
Phase: PHASE3 • Sponsor: Zealand Pharma • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug called ZP9830 calm psoriasis Flare-Ups?
Symptom relief Recruiting nowThis trial investigates whether an experimental drug, ZP9830, can safely improve symptoms of plaque psoriasis when taken over 8 weeks. The study includes adults with stable plaque psoriasis who have at least two visible plaques. Researchers will monitor side effects, measure how …
Phase: PHASE1 • Sponsor: Zealand Pharma • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Can a new injectable drug safely tackle weight? an early trial seeks answers
Knowledge-focused Recruiting nowThis early-stage trial is testing whether an experimental drug called ZP6590 is safe and how the body processes it. The study includes men with normal weight, overweight, and obesity. Some participants receive a single dose of ZP6590 or a placebo, while others receive multiple do…
Phase: EARLY_PHASE1 • Sponsor: Zealand Pharma • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Liver function may affect how Weight-Loss drug petrelintide works
Knowledge-focused Recruiting nowThis study tests how the experimental weight-loss drug petrelintide is processed in people with mild to moderate liver impairment compared to those with healthy livers. Researchers will measure drug levels in the blood after a single injection. The goal is to see if liver problem…
Phase: PHASE1 • Sponsor: Zealand Pharma • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
New drug ZP9830 enters first human safety study
Knowledge-focused Recruiting nowThis early-stage trial tests the safety and tolerability of a new drug called ZP9830 in 124 healthy adults aged 18-45. Participants receive either the drug or a placebo, given as an injection under the skin or into a vein. The study aims to understand how the drug behaves in the …
Phase: PHASE1 • Sponsor: Zealand Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC